Yocham v. Novartis Pharmaceuticals Corp.

565 F. Supp. 2d 554, 2008 U.S. Dist. LEXIS 59234, 2008 WL 2766172
CourtDistrict Court, D. New Jersey
DecidedJune 16, 2008
DocketCivil 07-1810 (JBS)
StatusPublished
Cited by30 cases

This text of 565 F. Supp. 2d 554 (Yocham v. Novartis Pharmaceuticals Corp.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Yocham v. Novartis Pharmaceuticals Corp., 565 F. Supp. 2d 554, 2008 U.S. Dist. LEXIS 59234, 2008 WL 2766172 (D.N.J. 2008).

Opinion

OPINION

SIMANDLE, District Judge:

Plaintiff Cordelia Yocham filed this action against Defendant Novartis Pharmaceuticals Corporation (“Novartis”), alleging that she was injured as a result of ingesting Lamisil, a product manufactured by Defendant. Plaintiff, a Texas resident, filed this lawsuit in New Jersey, where Defendant’s corporate offices are located and where the product at the heart of her claims was tested and marketed. Present *556 ly before the Court is Defendant’s motion [Docket Item 21] to transfer venue from this Court to the Northern District of Texas, pursuant to 28 U.S.C. § 1404(a). For the reasons set forth below, the Court will deny Defendant’s motion.

I. BACKGROUND

This lawsuit arises out of Plaintiffs allegation that she developed Steven-Johnson Syndrome (“SJS”), a painful and potentially life-threatening medical condition, as a result of having ingested Lamisil, a prescription antifungal medication manufactured and distributed by Defendant. (Compile 10-13.) Plaintiff, who resides in Ballinger, Texas, was prescribed Lamisil by her physician on April 14, 2005 to treat a toenail or fingernail infection. (Id. at ¶¶ 2, 7.) Plaintiff alleges that within two weeks of having used Lamisil, she developed a rash, and not long thereafter, she was admitted to the hospital and diagnosed with SJS. (Id. at ¶ 11.) Plaintiff was in the hospital for five days and alleges that she was permanently injured from the SJS that she alleges was the result of having taken Lamisil. (Id. at ¶¶ 13,17.)

Plaintiff filed this action against Defendant in the Superior Court of New Jersey on April 5, 2007. (Docket Item 1.) Her Complaint asserts claims of negligence (Count I), strict liability (Count II), breach of express warranty (Count III), breach of implied warranty (Count IV), fraudulent misrepresentation (Count V), negligent and reckless misrepresentation (Count VI), unjust enrichment (Count VII), defective design and failure to warn under the New Jersey Product Liability Act (Counts VIII and IX), and a New Jersey Consumer Fraud Act claim (Count X). 1

In her Complaint, Plaintiff alleged that venue in the Superior Court of New Jersey was proper because Novartis’ principal place of business is located in New Jersey. (CompU 3.) The documentation Plaintiff has submitted in opposing Defendant’s motion indicates that at least some of the clinical studies on the toxicity and side effects of Lamisil were performed in New Jersey, (Pl.’s Opp’n Br. Ex. A at 4), and Plaintiff has represented that Defendant developed and marketed Lamisil in New Jersey. (Pl.’s Opp’n Br. Exs. A-F.)

Novartis timely removed this action to this Court on April 17, 2007. (Docket Item 1.) Plaintiff subsequently moved to remand this case back to the Superior Court of New Jersey, and on August 13, 2007, the Court issued an Opinion and Order denying Plaintiffs motion. (Docket Items 17 and 18.) Defendant then filed the motion to transfer venue presently under consideration.

II. DISCUSSION

A. Section 1404(a) Standard

Under 28 U.S.C. § 1404(a), “fflor the convenience of parties and witnesses, in the interest of justice, a district court may transfer any civil action to any other district or division where it might have been brought.” 2 The Court of Appeals has explained that

*557 [i]n ruling on § 1404(a) motions, courts have not limited their consideration to the three enumerated factors in § 1404(a) (convenience of parties, convenience of witnesses, or interests of justice), and, indeed, commentators have called on the courts to consider all relevant factors to determine whether on balance the litigation would more conveniently proceed and the interests of justice be better served by transfer to a different forum.

Jumara v. State Farm Ins. Co., 55 F.3d 873, 879 (3d Cir.1995) (internal quotations and citations omitted). Courts ruling on § 1404(a) motions have accordingly taken into account a wide range of public and private interests in determining whether a transfer is appropriate.

Among the private interests that the Jumara court identified as being significant to the § 1404(a) analysis are:

plaintiffs forum preference as manifested in the original choice; the defendant’s preference; whether the claim arose elsewhere; the convenience of the parties as indicated by their relative physical and financial condition; the convenience of the witnesses — but only to the extent that the witnesses may actually be unavailable for trial in one of the fora; and the location of books and records (similarly limited to the extent that the files could not be produced in the alternative forum).

Id. at 879 (citations omitted). Among the public interests to be considered are:

the enforceability of the judgment; practical considerations that could make the trial easy, expeditious, or inexpensive; the relative administrative difficulty in the two fora resulting from court congestion; the local interest in deciding local controversies at home; the public policies of the fora; and the familiarity of the trial judge with the applicable state law in diversity cases.

Id. at 879-80 (citations omitted). It is well-settled that the burden on a § 1404(a) motion must be borne by the party seeking to transfer the case, and that “the motion must not be lightly granted.” Wright, Miller & Cooper, Federal Practice and Procedure: Jurisdiction 3d § 3848; see also Shutte v. Armco Steel Corp., 431 F.2d 22, 25 (3d Cir.1970) (noting that “[t]he decision to transfer is in the court’s discretion, but a transfer is not to be liberally granted”) (citation omitted).

B. Application of Section 1404(a) to this Case

In support of its motion, Defendant argues that this case should be transferred to the District Court for the Northern District of Texas, because, as Plaintiffs state of residence and the state where Plaintiffs injuries occurred and medical treatment was rendered, Texas is a more convenient, appropriate venue than New Jersey. 3 As the Court explains below, it *558 finds that the private interests in this case weigh strongly against transfer, that the public interests do not tip as heavily against transfer, and that Defendant’s motion should thus be denied.

1. Private Interest Considerations

First, the Court finds that the private interest considerations in this case weigh against transfer.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
565 F. Supp. 2d 554, 2008 U.S. Dist. LEXIS 59234, 2008 WL 2766172, Counsel Stack Legal Research, https://law.counselstack.com/opinion/yocham-v-novartis-pharmaceuticals-corp-njd-2008.